Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity (2015 - 2026)

Axsome Therapeutics has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $713.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $713.6 million, up 19.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 19.24% YoY), and the FY2025 annual result was $689.8 million, up 21.34% from the prior year.
• Liabilities and Shareholders Equity came in at $713.6 million for Q1 2026 at Axsome Therapeutics, up from $689.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $713.6 million in Q1 2026 to a low of $88.6 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $568.5 million (2024), against an average of $509.6 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 46.94% in 2022 and surged 339.45% in 2023, its largest moves.
• Axsome Therapeutics' Liabilities and Shareholders Equity stood at $331.5 million in 2022, then surged by 77.46% to $588.2 million in 2023, then retreated by 3.36% to $568.5 million in 2024, then rose by 21.34% to $689.8 million in 2025, then gained by 3.45% to $713.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $713.6 million (Q1 2026), $689.8 million (Q4 2025), and $669.2 million (Q3 2025), per Business Quant data.